Literature DB >> 10930969

Compliance with tricyclic antidepressants: the value of four different methods of assessment.

C F George1, R C Peveler, S Heiliger, C Thompson.   

Abstract

AIMS: To assess the advantages and disadvantages of four methods for studying compliance with antidepressants: self-report scores, tablet counts, a microprocessor (MEMS) container system and the assay of nordothiepin and dothiepin concentrations in plasma.
METHODS: The techniques were used in 88 patients commencing tricyclic antidepressants in the setting of UK general practice.
RESULTS: The MEMS system proved to be the most informative technique allowing identification of the precise time of container opening, the demonstration of 'drug holidays' and early cessation of therapy. Self-report scores (Morisky) proved a useful screening technique with a sensitivity of 72.2% and specificity of 74.1% for > or = 80% compliance. Although tablet counts were possible in 84 patients (95. 5%) they were unreliable in 19 (21.6%). Blood concentration assays proved the least acceptable method to patients and were possible in only 53 (60.2%). A ratio of nordothiepin:dothiepin > or = 1.1 claimed, by others, to identify noncompliance was only reliable when concentrations were low.
CONCLUSIONS: Both the MEMS system and self-report scores proved useful methods for identifying noncompliant patients in the setting of UK general practice. Although compliance was higher than reported in previous studies with 70 patients (79.5%) completing 6 weeks treatment, general practitioners tended to prescribe subtherapeutic doses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10930969      PMCID: PMC2014396          DOI: 10.1046/j.1365-2125.2000.00244.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

Review 1.  Recognition and management of depression in general practice: consensus statement.

Authors:  E S Paykel; R G Priest
Journal:  BMJ       Date:  1992-11-14

2.  The rational clinical examination. Is this patient taking the treatment as prescribed?

Authors:  B J Stephenson; B H Rowe; R B Haynes; W M Macharia; G Leon
Journal:  JAMA       Date:  1993-06-02       Impact factor: 56.272

3.  Plasma concentrations, information and therapy adherence during long-term treatment with antidepressants.

Authors:  A C Altamura; M Mauri
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

4.  Effect of antidepressant drug counselling and information leaflets on adherence to drug treatment in primary care: randomised controlled trial.

Authors:  R Peveler; C George; A L Kinmonth; M Campbell; C Thompson
Journal:  BMJ       Date:  1999-09-04

5.  High performance liquid chromatographic determination of dothiepin and northiaden in human plasma and serum.

Authors:  R R Brodie; L F Chasseaud; E L Crampton; D R Hawkins; P C Risdall
Journal:  J Int Med Res       Date:  1977       Impact factor: 1.671

6.  Continuation therapy with amitriptyline in depression.

Authors:  A Coppen; K Ghose; S Montgomery; V A Rama Rao; J Bailey; A Jorgensen
Journal:  Br J Psychiatry       Date:  1978-07       Impact factor: 9.319

7.  Concurrent and predictive validity of a self-reported measure of medication adherence.

Authors:  D E Morisky; L W Green; D M Levine
Journal:  Med Care       Date:  1986-01       Impact factor: 2.983

8.  Drug defaulting in a general practice.

Authors:  A M Porter
Journal:  Br Med J       Date:  1969-01-25

Review 9.  Compliance during tricyclic antidepressant therapy: pharmacokinetic and analytical issues.

Authors:  J M Perel
Journal:  Clin Chem       Date:  1988-05       Impact factor: 8.327

10.  Plasma concentrations of dothiepin and its metabolites are not correlated with clinical efficacy in major depressive illness.

Authors:  K F Ilett; T H Blythe; L P Hackett; R T Ong; D A Tannenbaum; T M Clarke
Journal:  Ther Drug Monit       Date:  1993-10       Impact factor: 3.681

View more
  60 in total

1.  Is concordance the primrose path to health?

Authors:  Robin E Ferner
Journal:  BMJ       Date:  2003-10-11

2.  Risk factors for medication misadventure among residents in sheltered housing complexes.

Authors:  Johnson George; Kim Munro; Dorothy McCaig; Derek Stewart
Journal:  Br J Clin Pharmacol       Date:  2006-10-31       Impact factor: 4.335

3.  Factor structure and validity of the Medication Adherence Questionnaire (MAQ) with cigarette smokers trying to quit.

Authors:  Benjamin A Toll; Sherry A McKee; Daniel J Martin; Peter Jatlow; Stephanie S O'Malley
Journal:  Nicotine Tob Res       Date:  2007-05       Impact factor: 4.244

4.  [Adherence to psychopharmacological treatment: Psychotherapeutic strategies to enhance adherence].

Authors:  R Lencer; D Korn
Journal:  Nervenarzt       Date:  2015-05       Impact factor: 1.214

5.  Impact of the Chronic Care Model on medication adherence when patients perceive cost as a barrier.

Authors:  Katherine Mackey; Michael L Parchman; Luci K Leykum; Holly J Lanham; Polly H Noël; John E Zeber
Journal:  Prim Care Diabetes       Date:  2012-01-20       Impact factor: 2.459

6.  Predictors of refill non-adherence in patients with heart failure.

Authors:  Johnson George; Stephen J Shalansky
Journal:  Br J Clin Pharmacol       Date:  2006-10-31       Impact factor: 4.335

7.  Predictors of non-adherence to pharmacotherapy in patients with type 2 diabetes.

Authors:  Anan S Jarab; Reham Almrayat; Salam Alqudah; Ekbal Thehairat; Tareq L Mukattash; Maher Khdour; Sharrel Pinto
Journal:  Int J Clin Pharm       Date:  2014-05-08

8.  Determinants of compliance with malaria chemoprophylaxis among French soldiers during missions in inter-tropical Africa.

Authors:  Noémie Resseguier; Vanessa Machault; Lénaick Ollivier; Eve Orlandi-Pradines; Gaetan Texier; Bruno Pradines; Jean Gaudart; Alain Buguet; Catherine Tourette-Turgis; Christophe Rogier
Journal:  Malar J       Date:  2010-02-03       Impact factor: 2.979

9.  The MATISSE study: a randomised trial of group art therapy for people with schizophrenia.

Authors:  Mike J Crawford; Helen Killaspy; Eleftheria Kalaitzaki; Barbara Barrett; Sarah Byford; Sue Patterson; Tony Soteriou; Francis A O'Neill; Katie Clayton; Anna Maratos; Thomas R Barnes; David Osborn; Tony Johnson; Michael King; Peter Tyrer; Diana Waller
Journal:  BMC Psychiatry       Date:  2010-08-27       Impact factor: 3.630

10.  Importance of dose timing to achieving undetectable viral loads.

Authors:  Christopher J Gill; Lora L Sabin; Davidson H Hamer; Xu Keyi; Zhang Jianbo; Tao Li; Wan-Ju Wu; Ira B Wilson; Mary Bachman Desilva
Journal:  AIDS Behav       Date:  2009-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.